ViiV Healthcare: Gilead, GSK-ViiV move ahead with long-acting HIV options following early-stage readouts

Gilead plans to go straight to Phase III studies for once-yearly lenacapavir, while GSK and Viiv will push forward with their long-acting antivirals after touting positive early-stage results.The post Gilead, GSK-ViiV move ahead with long-acting HIV options following early-stage readouts appeared first on PharmaLive.